Will Stone
Stories
-
FDA gives thumbs down to MDMA for now, demanding further research
The much-anticipated decision has rattled supporters of psychedelic therapies. The drugmaker says it will ask the agency to reconsider.
-
Can a lobbying push led by veterans help MDMA get approved for PTSD treatment?
Advocates are still fighting to get the psychedelic drug approved as a mental health treatment, despite its rejection by the FDA's advisory committee in June. They face an uphill battle.
-
With the U.S. bird flu outbreak uncontained, scientists see growing risks
A recent crop of human cases at a chicken farm highlight the risks of the ongoing outbreak. Here's what scientists fear could happen next in the evolution of the virus.
-
More Americans are microdosing or tripping on magic mushrooms than ever
Two new studies estimate psychedelic use in the U.S. and both find magic mushrooms gaining in popularity, including some folks who just want to get a little bit high, aka microdosing.
-
Your gut microbes may influence how you handle stress
A new study finds people who are resilient in the face of stressful events have a different mix of microorganisms in the gut than those who get more frazzled.
-
Scientists look at the connection between gut health and resilience to stress
Scientists are trying to decode how the trillions of microorganisms in our gut talk with the brain and shape our resilience to stress. A new study offers some initial clues.
-
Bird flu risk is restricted to those who work with dairy cattle — for now
More cattle are getting the bird flu virus, and it appears that people are a big factor in spreading it from herd-to-herd. NPR's Danielle Kurtzleben talks to NPR Health correspondent Will Stone.
-
In 'Good Energy,' a doctor lays out how to measure and boost your metabolic health
In her new book, Dr. Casey Means argues that good metabolic function is key to preventing chronic disease. And she shares a prescription for boosting yours.
-
Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics
Psychedelics researchers and investors are still reeling from last week’s no vote for MDMA by a panel of advisers to the FDA.